| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/26/2011 | CA2446619C Permeation enhancers |
| 04/26/2011 | CA2446112C A method for regulating immune function in primates using the foxp3 protein |
| 04/26/2011 | CA2415397C Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 04/26/2011 | CA2408838C Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/26/2011 | CA2298934C Vectors derived from antibodies for transferring substances into cells |
| 04/26/2011 | CA2264012C Compositions and methods for polynucleotide delivery |
| 04/26/2011 | CA2215394C Il-17 receptor |
| 04/26/2011 | CA2201482C Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 04/21/2011 | WO2011047318A2 Supercoiled minicircle dna for gene therapy applications |
| 04/21/2011 | WO2011046983A2 Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| 04/21/2011 | WO2011046700A1 Cftr-activating enhancer |
| 04/21/2011 | WO2011046570A1 Method for treating chronic nerve tissue injury using a cell therapy strategy |
| 04/21/2011 | WO2011045765A1 TEMPORALLY PATTERNED OVEREXPRESSION OF Foxg1 AND Emx2 TRANSCRIPTION FACTOR GENES IN NEURAL PRECURSORS FOR BRAIN TISSUE REPAIR |
| 04/21/2011 | WO2011045747A1 Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy |
| 04/21/2011 | WO2011044721A1 Use of spink6 gene and protein encoded therein in the manufacture of anti-tumor medicaments |
| 04/21/2011 | WO2011017297A3 Liposomes comprising a calcium phosphate - containing precipitate |
| 04/21/2011 | WO2011011725A3 Use of toxoplasma and derived compositions to prevent or treat microbial infections |
| 04/21/2011 | WO2010144324A3 Use of stamp related molecules in the diagnosis and inhibition of ovarian cancer cells |
| 04/21/2011 | WO2010141842A3 Interlaced method for treating cancer or a precancerous condition |
| 04/21/2011 | WO2010141471A3 Nucleic acid delivery compositions and methods of use thereof |
| 04/21/2011 | WO2010137890A3 Composition for improving the viability and proliferation ability of stem cells |
| 04/21/2011 | US20110092673 Isolated Antibodies Against Biologically Active Leptin-Related Peptides |
| 04/21/2011 | US20110092577 Inositol Pyrophosphates Determine Exocytotic Capacity |
| 04/21/2011 | US20110092565 Method of treating neurodegenerative disease |
| 04/21/2011 | US20110092421 Methods for generating new hair follicles, treating baldness, and hair removal |
| 04/21/2011 | US20110091920 METHOD OF DIAGNOSING A CLINICAL CONDITION BY DETECTION OF A PAPP-A/proMBP COMPLEX |
| 04/21/2011 | US20110091892 Methods for the Diagnosis and Treatment of Lung Cancer |
| 04/21/2011 | US20110091505 Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen |
| 04/21/2011 | US20110091504 Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen |
| 04/21/2011 | US20110091469 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 04/21/2011 | US20110091429 Methods for Enhancing Stem Cell Engraftment During Transplantation |
| 04/21/2011 | US20110091425 Upregulation of opioid receptors for management |
| 04/21/2011 | US20110091420 Injectable Sustained-Release Pharmaceutical Formulation and the Preparation Method Thereof |
| 04/21/2011 | US20110091407 Polymer derived from linear polyethylenimine for gene transfer |
| 04/21/2011 | CA2780741A1 Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| 04/20/2011 | EP2311980A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311979A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/20/2011 | EP2311978A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311973A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/20/2011 | EP2311958A2 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 04/20/2011 | EP2311955A2 Osteoprotegerin binding proteins and their receptors |
| 04/20/2011 | EP2311953A1 Bone/joint disease susceptibility gene and use thereof |
| 04/20/2011 | EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311948A1 RNA-interference for ZNFN3A1-gene as a method for inhibiting cancer cell growth |
| 04/20/2011 | EP2311944A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311869A1 Use of mammalian cytokine; related reagents |
| 04/20/2011 | EP2311862A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311861A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311860A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311495A1 Vascularization inhibitors |
| 04/20/2011 | EP2311487A2 Identification of surface-associated antigens for tumour diagnosis and therapy |
| 04/20/2011 | EP2311469A2 Methods and compositions for tissue regeneration |
| 04/20/2011 | EP2311466A2 Antimicrobial compounds and methods for their use |
| 04/20/2011 | EP2310510A2 Idna vaccines and methods for using the same |
| 04/20/2011 | EP2310500A1 Methods for optimizing electroporation |
| 04/20/2011 | EP2310054A2 Aptamer inhibition of thrombus formation |
| 04/20/2011 | EP2310039A1 Fgf-9 and its use relating to blood vessels |
| 04/20/2011 | EP1899487B1 Gfats as modifiers of the axin pathway and methods of use |
| 04/20/2011 | EP1626090B1 Novel virus vector |
| 04/20/2011 | EP1625142B1 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
| 04/20/2011 | EP1427826B1 HIV- RT-nef-Gag codon optimised DNA vaccines |
| 04/20/2011 | EP1385993B1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 04/20/2011 | EP1224461B1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 04/20/2011 | EP1082415B1 Methods useful for modulation of angiogenesis using tyrosine kinase src |
| 04/20/2011 | CN1849395B HLA-a24 binding cancer antigen peptide derived from ribin |
| 04/20/2011 | CN1628179B Detection of hepatocellular carcinoma |
| 04/20/2011 | CN102027123A Recombinant production of authentic human proteins using human cell expression systems |
| 04/20/2011 | CN102027114A Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
| 04/20/2011 | CN102027019A High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
| 04/20/2011 | CN102026672A C2ORF18 as target gene for cancer therapy and diagnosis |
| 04/20/2011 | CN102026670A Novel siRNA compounds for inhibiting RTP801 |
| 04/20/2011 | CN102026647A Pharmaceutical composition for treating or preventing cancer which induces dendritic cell-like differentiation of monocytes to increase anticancer immune activity |
| 04/20/2011 | CN102026645A Oncolytic rhabdovirus |
| 04/20/2011 | CN102021200A Recombinant virus vector and application thereof |
| 04/20/2011 | CN102021175A Optimized grass carp alpha interferon encoding gene and application thereof |
| 04/20/2011 | CN102021170A Small interfering ribonucleic acid (siRNA) molecule of interfering hepatitis B virus gene and application thereof |
| 04/20/2011 | CN102021165A schistosoma japonicum miRNA and application thereof |
| 04/20/2011 | CN102021160A Snake venom serine protease and coding gene and application thereof |
| 04/20/2011 | CN102021153A Human telomerase catalytic subunit |
| 04/20/2011 | CN102018965A Application of miRNA-10a in preparation of drug inhabiting intrusion and transfer of colorectal cancer |
| 04/20/2011 | CN102018964A Three-plasmid co-immune vaccine system capable of breaking immune tolerance and preparation method thereof |
| 04/20/2011 | CN102018963A MiR-125a for adjusting regulated on activation normal T cell expressed and secreted (RANTES) expressions as well as composition and application thereof |
| 04/20/2011 | CN102018959A Method and reagent for preventing and treating heart disease |
| 04/20/2011 | CN101670117B Application of miR-146a in preparing medicine for curing gastricism |
| 04/20/2011 | CN101619312B Long non-coding RNA sequence of human melanoma cell specific expression and application thereof |
| 04/20/2011 | CN101612406B siRNA aiming at RMP gene and application thereof |
| 04/20/2011 | CN101580845B Vector capable of inducing cancer cell-apoptosis and use thereof |
| 04/20/2011 | CN101423555B Membrane penetrating polypeptide for specific inhibition of hepatitis b virus assembly and replication |
| 04/20/2011 | CN101100487B Fusion protein capable of removing HPV E7 protein and its encoding gene and application |
| 04/20/2011 | CN101024090B Gene transferring compound and its preparing method |
| 04/19/2011 | US7928220 for treating ocular disease, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of SDF-1 in a cell or tissue |
| 04/19/2011 | US7928219 chemically modified nucleic acid molecule; cancer; carcinoma, neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases, restenosis and polycystic kidney disease |
| 04/19/2011 | US7928218 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 04/19/2011 | US7928217 Drug delivery of nucleotide into tumor; antitumor biodrugs; stability in cells; prevent gene expression of target genes |
| 04/19/2011 | US7928216 Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases |
| 04/19/2011 | US7928213 Nucleic acids encoding chimeric CD154 polypeptides |
| 04/19/2011 | US7928199 Stabilized proteins with engineered disulfide bonds |
| 04/19/2011 | US7928197 Feline IL-18 proteins |